Navigation Links
FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
Date:11/20/2007

HENDERSON, Nev., Nov. 20 /PRNewswire/ -- FDA spokesman, Brad Swezey, affirmed to the Wall Street Journal (WSJ) yesterday that the FDA had not received any reports of patient injuries or adverse effects related to use of the eyelash product the agency seized last Friday.

According to its November 16, 2007, news release, the FDA seized an eyelash product (not made by Athena Cosmetics) because the agency had concerns that an ingredient in the product, bimatoprost, could possibly have deleterious side effects if it were improperly used in the eye with a medication used to treat glaucoma that also contains bimatoprost. As affirmed by Mr. Swezey in a November 19th WSJ article, the FDA did not seize the eyelash product because the FDA or the company that made the product had received reports of any of the serious side effects listed in the FDA's news release.

The FDA's action has created some public concern about the safety of similar eyelash products sold by Athena Cosmetics, Inc. and other companies. Athena Cosmetics wants to assure its customers that, as confirmed by the FDA for the product it seized, there have been no reports of patient injuries or significant adverse effects from thousands of satisfied RevitaLash(R) customers. To the contrary, only a very small number of RevitaLash(R) consumers have reported minor, temporary side effects such as irritation or redness. In addition, the safety of RevitaLash(R) has been tested in two clinical tests conducted by a reputable research laboratory. No adverse reactions were observed in either clinical study of RevitaLash(R).

RevitaLash(R) was developed by an ophthalmologist, Dr. Michael Brinkenhoff, the founder of Athena Cosmetics. As a practicing physician, Dr. Brinkenhoff formulated RevitaLash(R) with safety as the highest priority. Thousands of happy and satisfied customers have safely used RevitaLash(R) to enhance the beauty of their eyelashes. While Athena Cosmetics is confident that RevitaLash(
'/>"/>

SOURCE Athena Cosmetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
2. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
3. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
6. OTC Anti-Aging Products: Hype or Hope?
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
11. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... Ariz., Dec. 6 The FDA has ... detect breast cancer sooner and faster. The SonoCine ... by only one facility in Arizona - Arizona ... specifically as a breast cancer screening tool to ... only been used for diagnostic purposes - not ...
(Date:12/4/2009)... 4 A simple, inexpensive computer tool that measures ... the lungs picked up by a CT scanner can ... enable doctors to diagnose true cancers with fewer, less ... ) ,, The new diagnostic guidelines are described in ...
(Date:12/4/2009)... Inc. (VRML) (Pink Sheets: VRMLQ) announced that on December 3, ... related amended Disclosure Statement with the United States Bankruptcy Court ... to consider the adequacy of the Disclosure Statement is presently ... confirmation of the Plan scheduled for January 7, 2010. ,, ...
Breaking Medicine Technology:New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Prototype NIST method detects and measures elusive hazards 14913 1Prototype NIST method detects and measures elusive hazards 14913 2Opto electronic nose sniffs out toxic gases 14911 1Opto electronic nose sniffs out toxic gases 14911 2Opto electronic nose sniffs out toxic gases 14911 3AmeriCares and Boeing Deliver Emergency Relief Supplies to the Philippines 61675 1AmeriCares and Boeing Deliver Emergency Relief Supplies to the Philippines 61675 2
... PGL; NASDAQ: PGLA) is pleased to announce that its ... late breaking news,presentation by the European Association for the ... the results of this liver,cancer trial at the American ... ,In expectation of having final data fully analysed and ...
... 13, 2007 -,Cytos Biotechnology AG (SWX:CYTN) reported ... with CYT003-QbG10, an immunotherapeutic,product candidate for the ... patients suffering from mild to moderate allergic,rhinitis ... The trial,investigated in a doubleblind setting the ...
Other Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7
(Date:12/6/2009)... Dec. 6 Sickle cell disease, a ... cells, is one of the most common genetic ... world, including more than 70,000 Americans.(1) Research presented ... American Society of Hematology highlights intriguing studies on ... for children with this blood disorder, evaluations of ...
(Date:12/6/2009)... ON. Dec. 6, 2009 A new study provides ... known as venous thromboembolism (VTE). , The condition ... every year, and occurs when an abnormal clot forms ... causing pain and swelling. In some cases, the clot ... through the heart to the lungs, causing a potentially ...
(Date:12/6/2009)... members of the community, in cooperation with the Greater VA Healthcare ... party. This year,s attendance is expected to soar to more than ... , ... (PRWEB) December 6, 2009 -- Volunteer organizations and ... System in West Los Angeles, will once again create a holiday ...
(Date:12/5/2009)... combination has shown in a phase 1/2 clinical ... the treatment of patients newly diagnosed with multiple myeloma, ... say researchers from Dana-Farber Cancer Institute. , Partial responses ... patients treated with the drug combination in the multi-center ... response rate" in the phase 2 population, reports Paul ...
(Date:12/5/2009)... ,, What: Cuts for a Cause ,, ... against cancer and other terminal illnesses affecting children. All proceeds ... Jude Children,s Research Hospital. Guests will enjoy complimentary beverages and ... Vietnamese restaurant in Falls Church for all guests. Hoa Lai, ...
Breaking Medicine News(10 mins):Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2
... to relieve anxiety symptoms, and valerian used for insomnia,// ... reported in the first research study to be monitored ... of the journal Medicine., ,The researchers Dr. Bradly ... Francisco had performed an innovative Internet trial to evaluate ...
... recent study researchers say that latest research suggests that ... ineffective for women who lack a gene called the ... drugs did not improve ovulation rates in mice that ... estrogen receptor beta is one of two estrogen receptor ...
... found that Post-menopausal// women has an increased chance of loosing ... Periodontology, which was conducted in 106 Post-menopausal women during a ... the women in the study lost at least one tooth. ... Post-menopausal women, as studies has proved that loss of each ...
... involving 3,189 school children from Denmark, Estonia and Portugal// ... worse health compared to children from children’s of rich ... published in British Medical Journal. The results of the ... that adverse social circumstances in childhood may cause an ...
... that death among men from lung cancer is now ... among women. ,Lung cancer continues to be the leading ... have reported that lung cancer deaths among men are ... states from central and eastern Europe, but they are still ...
... how the heart fails, and hope that this may make ... worked to find out how the metabolic pathways differentiate in ... early stages of heart failure, the heart uses too much ... doesn't use enough fat., ,Gary Lopaschuk, a pharmacologist and ...
Other Medicine News:Health News:Herbal Remedies For Insomnia And Anxiety May Be Ineffective 2Health News:New Discovery May Help Treat Infertility 2Health News:Post-Menopausal Status May Cause Tooth Decay 2Health News:Lung Cancer Deaths Declining In Men But Not Women In European Countries 2Health News:Details Of Heart Failure Discovered 2
... quick and easy automated refill system ... space on your laboratory bench and ... easy-to-use, one-hand system, you only need ... of Diamond Tips. All sizes of ...
10 L, Stacked Rack, 96 tips/rack 5 racks/stack, clear Recommended for 2, 5, 10 L pipettes....
... been designed to optimize the accuracy and ... tip products is widely recognized by customers ... been extended over the years and now ... special tips including filter tips, certified pure ...
... HerpeSelect® 2 ELISA IgG test is intended ... human IgG class antibodies to HSV-2 in ... 1 ELISA IgG, the test is indicated ... for aiding in the presumptive,diagnosis of HSV ...
Medicine Products: